

Louisiana Medicaid Copper Histidinate (Zycubo®)

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for copper histidinate (Zycubo®).

Additional Point-of-Sale edits may apply.

By submitting the authorization request, the prescriber attests to the conditions available [HERE](#).

Approval Criteria for Initiation of Therapy

- The recipient is less than 18 years of age on the date of the request; **AND**
- **ONE** of the following applies and is **stated on the request**:
 - The recipient has a diagnosis of Menkes disease confirmed by genetic testing which demonstrates a mutation in the *ATP7A* gene; **OR**
 - The recipient has signs and symptoms suggestive of Menkes disease and will be treated presumptively while awaiting genetic confirmation (in this situation, genetic confirmation must be submitted for reauthorization); **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a geneticist or neurologist.

Duration of approval for initiation of therapy: 3 months

Approval Criteria for Continuation of Therapy

- The prescriber **states on the request** that the recipient is established on the medication with evidence of a positive response to therapy; **AND**
- If the recipient was treated presumptively with Zycubo® while awaiting genetic testing results, the prescriber **states on the request** that genetic testing confirms the diagnosis of Menkes disease.

Duration of approval for continuation of therapy: 12 months

References

Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, Liew CJ, Sato S, Patronas N. Neonatal diagnosis and treatment of Menkes disease. *N Engl J Med*. 2008 Feb 7;358(6):605-14. doi: 10.1056/NEJMoa070613. PMID: 18256395; PMCID: PMC3477514.

Zycubo (copper histidinate) [package insert]. Solana Beach, CA: Sentyln Therapeutics, Inc; January 2026. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e3aeefc2-f44d-4337-9c2e-3dba44a89e48&type=display>

Revision / Date	Implementation Date
Policy created / February 2026	July 2026